Monitor for upcoming 10-K or 8-K filings for potential disclosures on executive departures, slowed development timelines, or lack of partnership progress. Consider this insider selling as a cautionary signal, especially given the concentration among C-suite executives.
Price Chart
Executive Summary
Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold shares in a concentrated 7-day window, including the Chief Development Officer, CFO, and Chief Commercial Officer, realizing over $157,000 in total proceeds. The transactions include both cash sales and share movements (M) with no stated value, suggesting possible pre-arranged 10b5-1 plans or equity settlements. The cluster of insider selling by top executives raises caution despite lack of explicit negative filing disclosures.
Key Financial Metrics
Key Facts
- Chief Development Officer Christopher Yea sold 4,347 shares for $67,669.
- CFO Brian Piekos sold 1,767 shares for $27,507.
- Chief Commercial Officer Nicole Sweeny sold 3,975 shares for $61,878.
- Total cash proceeds from insider sales: $157,054.
- All cash sales occurred at $15.5668 per share on 2026-02-23.
- Additional non-cash 'M' transactions (likely share releases or plan dispositions) totaling 18,125 shares across the three executives.
Financial Impact
$157,054 in insider selling over 7 days
Risk Factors
- Insider selling may indicate lack of confidence in near-term prospects.
- Potential for negative newsflow ahead (e.g., trial delays, funding concerns) not yet public.
- Non-cash 'M' transactions could signal broader equity disposition plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-KALV-1771980228290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 22, 2026 14w ago | 15-12G | — | awaiting T+1 | — | — |
Jun 17, 2026 15w ago | EFFECT | $27.00 awaiting T+1 | awaiting T+1 | — | — |
Jun 11, 2026 16w ago | 8-K | $26.99 awaiting T+1 | awaiting T+1 | — | — |
Jun 11, 2026 16w ago | Institutional Cluster | $27.00 $27.00 | · 0.00% | ▼ −0.54% | — |
May 19, 2026 19w ago | Insider Cluster | $26.81 $26.77 | ▲ +0.15% | ▲ +0.34% | — |
May 19, 2026 19w ago | Insider Cluster | $26.81 $26.77 | ▼ −0.15% | ▼ −0.34% | — |
Apr 29, 2026 22w ago | 8-K | $26.67 $26.66 | ▼ −0.04% | ▼ −1.06% | — |
Apr 17, 2026 24w ago | Insider Cluster | $20.48 $20.87 | ▼ −1.90% | ▼ −2.10% | — |
Feb 23, 2026 31w ago | Insider Cluster | $15.56 $15.77 | ▼ −1.35% | ▼ −0.61% | — |
Feb 23, 2026 31w ago | Insider Cluster | $15.56 $15.77 | ▼ −1.35% | ▼ −0.61% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access